ASX:MYXPharmaceuticals
Are Mayne Pharma Group (ASX:MYX) Shares Undervalued As Earnings Contract?
Mayne Pharma Group shares have slipped over the past week even after closing at A$3.01, leaving short term traders unimpressed. Yet the latest full year numbers tell a tougher story than the headline share price suggests. Revenue for FY26 came in at A$383.7m with underlying earnings before interest, tax, depreciation and amortisation of A$34.2m, both weaker than last year.
The real pivot is in the outlook. Consensus points to earnings decline over the next three years, even as the stock...